Featured Research

from universities, journals, and other organizations

Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests

Date:
January 10, 2008
Source:
Cell Press
Summary:
The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose weight, even at very low doses. Short-term studies also suggest that the drug, called taranabant -- the second drug designed to fight obesity by blocking cannabinoid receptors in the brain -- seems to cause people to consume fewer calories and burn more energy.

The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose weight, even at very low doses. Short-term studies also suggest that the drug, called taranabant--the second drug designed to fight obesity by blocking cannabinoid receptors in the brain -- seems to cause people to consume fewer calories and burn more, researchers report in the January issue of Cell Metabolism, a publication of Cell Press. Cannabinoid receptors are responsible for the psychological effects of marijuana (Cannabis sativa), and natural "endocannabinoids" are important regulators of energy balance.

"The effects of marijuana on appetite have been known for millennia from its medicinal and recreational use," said study author Steven Heymsfield of Merck Research Laboratories. "The ingredient responsible stimulates cannabinoid receptors. When you block the cannabinoid system with an antagonist like taranabant, you suppress appetite." However, the drug, developed by Merck, also comes with an increased risk of adverse side effects at higher doses, the study shows, including mild to moderate gastrointestinal and psychiatric effects.

The first proof of concept that so-called cannabinoid 1 receptor (CB1R) inverse agonists might offer an obesity therapy came from studies of another drug, developed by Sanofi-Aventis, called rimonabant. That drug is now in use for weight loss in several European countries as an adjunct to diet and exercise but has not received FDA approval for use in the United States.

Taranabant is a structurally novel, highly selective, potent CB1R inverse agonist, Heymsfield's team said. Preclinical studies in animals showed that it can cause weight loss at doses that block just 30 percent of cannabinoid receptors. To extend those findings to humans in the new studies, the researchers first used positron emission tomography (PET) imaging to identify a dose that would bind about 30 percent of cannabinoid receptors in the human brain. They found that 4 to 6 milligrams of taranabant was enough to achieve that goal.

A multicenter, double-blind, placebo-controlled clinical trial including 533 obese patients showed that the drug induces significant weight loss at doses ranging from 0.5 to 6 milligrams. "That was surprising," Heymsfield said. "We didn't expect weight loss at all doses."

The researchers then conducted separate food intake and energy expenditure studies in overweight and moderately obese people who took a single 4- or 12-milligram dose of taranabant. Those studies showed that people taking 12 milligrams of the drug consumed 27 percent fewer calories than those taking a placebo. People taking the drug also expended more energy while at rest and appeared to burn more fat.

The studies also found that higher doses of the drug caused two types of adverse events, Heymsfield said. These negative side effects included gastrointestinal upset, including nausea and vomiting, as well as increased irritability. Marijuana is often used to combat the nausea associated with chemotherapy drugs, Heymsfield noted, and it also tends to make people mellower. "Here, again, [these drugs] have the opposite effect."

A larger, phase III clinical trial of taranabant is now underway to further explore its effects, Heymsfield said. "All we have here is 12 weeks; we don't yet know what will happen at six months or a year."

The researchers include Carol Addy, Merck Research Laboratories, Boston, MA; Hamish Wright, Merck Research Laboratories, Rahway, NJ; Koen Van Laere, Division of Nuclear Medicine, University Hospital and Katholieke Universiteit Leuven, Leuven, Belgium; Ira Gantz, Merck Research Laboratories, Rahway, NJ; Ngozi Erondu, Merck Research Laboratories, Rahway, NJ; Bret J. Musser, Merck Research Laboratories, Rahway, NJ; Kaifeng Lu, Merck Research Laboratories, Rahway, NJ; Jinyu Yuan, Merck Research Laboratories, Rahway, NJ; Sandra M. Sanabria-Bohorquez, Imaging Research, Merck Research Laboratories, West Point, PA; Aubrey Stoch, Merck Research Laboratories, Rahway, NJ; Cathy Stevens, Merck Research Laboratories, Rahway, NJ; Tung M. Fong, Merck Research Laboratories, Rahway, NJ; Inge De Lepeleire, MSD Europe, Inc., Brussels, Belgium; Caroline Cilissen, MSD Europe, Inc., Brussels, Belgium; Josee Cote, Merck Research Laboratories, Rahway, NJ; Kim Rosko, Merck Research Laboratories, Rahway, NJ; Isaias N. Gendrano III, Merck Research Laboratories, Rahway, NJ; Allison Martin Nguyen, Epidemiology, Merck Research Laboratories, Upper Gwynedd, PA; Barry Gumbiner, Merck Research Laboratories, Rahway, NJ; Paul Rothenberg, Merck Research Laboratories, Rahway, NJ; Jan de Hoon, Center for Clinical Pharmacology, Katholieke Universiteit Leuven, Leuven, Belgium; Guy Bormans, Division of Nuclear Medicine, University Hospital and Katholieke Universiteit Leuven, Leuven, Belgium; Marleen Depre, Center for Clinical Pharmacology, Katholieke Universiteit Leuven, Leuven, Belgium; Wai-si Eng, Imaging Research, Merck Research Laboratories, West Point, PA; Eric Ravussin, Division of Health and Performance Enhancement, Pennington Biomedical Research Center, Baton Rouge, LA; Samuel Klein, Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO; John Blundell, Institute of Psychological Sciences, University of Leeds, Leeds, UK; Gary A. Herman, Merck Research Laboratories, Rahway, NJ; H. Donald Burns, Imaging Research, Merck Research Laboratories, West Point, PA; Richard J. Hargreaves, Imaging Research, Merck Research Laboratories, West Point, PA; John Wagner, Merck Research Laboratories, Rahway, NJ; Keith Gottesdiener, Merck Research Laboratories, Rahway, NJ; John M. Amatruda, Merck Research Laboratories, Rahway, NJ; and Steven B. Heymsfield, Merck Research Laboratories, Rahway, NJ.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests." ScienceDaily. ScienceDaily, 10 January 2008. <www.sciencedaily.com/releases/2008/01/080108133347.htm>.
Cell Press. (2008, January 10). Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2008/01/080108133347.htm
Cell Press. "Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/01/080108133347.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins